Alex Melamed

Gynecologic Oncology practice @MassGenNews. Researching how real-world cancer care affects real-world patients. He/his/him/himself

[Alex Melamed @headofmelon]

New SGO evidence-based review on surgical management of cervical cancer in Gynecologic Oncology @gynoncjnls.

https://t.co/8deb4hLDC8

[Roni Nitecki Wilke @NiteckiRoni]

Excited to share our randomized controlled trial published in @JCO_ASCO showing that facilitated cascade testing increased genetic testing among relatives of individuals with BRCA1/2. @RauhHainMD @karenluMD @headofmelon @UTMDAnderson @MelissaFrey2

🔗 https://t.co/3YIfc0Ylot

[Alex Melamed @headofmelon]

What an honor to work with the amazing team that has turned @IJGConline into an academic powerhouse! @pedroramirezMD, thank you for your mentorship and for being our captain years. @RParejaGineOnco, so excited for your leadership going forward!

[IJGC @IJGConline]

Thank you, Alex @headofmelon for your outstanding service as IJGC #AssociateEditor 💙

💡 https://t.co/6unRs3hS3Q

@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde

[IJGC @IJGConline]

Thank you, Alex @headofmelon for your outstanding service as IJGC #AssociateEditor 💙

💡 https://t.co/6unRs3hS3Q

@pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde

[Alex Melamed @headofmelon]

Our latest lead by Dr. Katy Abel. More evidence that underutilization of NACT is associated with worse post-operative outcomes, without any hint of long-term benefit, even in high-volume centers.

[JAMA Network Open @JAMANetworkOpen]

For patients with advanced-stage ovarian cancer, higher utilization of neoadjuvant chemotherapy at high-volume centers was associated with the lowest 90-day surgical mortality and longest 60-month survival. https://t.co/NvOIMK7ZET

[Núria Agustí Garcia @nagustiga]

Our JAMA Oncology study is now featured in the @IJGConline podcast! Thank you for highlighting our work.

Grateful to work with such an amazing team! @dviverosc @headofmelon @NiteckiRoni @RParejaGineOnco @RauhHainMD

[Alex Melamed @headofmelon]

https://t.co/bwx6SuLOLI

[Núria Agustí Garcia @nagustiga]

Our 15-year cohort study explores trends in surgical de-escalation in gynecologic oncology. These findings are transforming patient care but raise important questions about the preparation of fellows in surgical training.
@headofmelon @dviverosc @RauhHainMD @NiteckiRoni

[Alex Melamed @headofmelon]

LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoreduction in ovarian cancer. @RauhHainMD @annafagottimd @RParejaGineOnco @pedroramirezMD @abedsinno

[JAMA Network Open @JAMANetworkOpen]

LANCE RCT: A minimally invasive surgery for advanced ovarian cancer after neoadjuvant chemotherapy is feasible and may reduce postoperative complications compared to laparotomy. https://t.co/ZfEn4aamYF

[Roni Nitecki Wilke @NiteckiRoni]

#cancer during #pregnancy is associated with severe maternal and neonatal morbidity. Proud of the entire team for this important manuscript!
https://t.co/qB7QRETVkK

@RauhHainMD @headofmelon @markaclapp @abigailflynt @dviverosc @nagustiga @MDAndersonNews @AJOG_thegray

[Alex Melamed @headofmelon]

What an honor for us to host @scambiagiovanni and @annafagottimd at @MghObgyn.

[Alex Melamed @headofmelon]

Cool picture of a adenosarcoma assocaited uterine inversion which we treated laparoscopically. Nice work by Baran Vardar and @AlexBercowMD getting these pictures into the literature.
https://t.co/D6Yy7Erjpp

[Alex Melamed @headofmelon]

https://t.co/pfYw7uNQmM

[Alex Melamed @headofmelon]

Josseli Barnica is the victim of a totalitarian state imposing its ideology on women’s bodies. America we are better than this.

[Alex Melamed @headofmelon]

NACT and interval cytoreductive surgery edges out primary cytoreductive surgery as the most frequent treatment for advanced-stage ovarian cancer in the US. 11 years after Vergote et al. It really does take a decade.

[JAMA Network Open @JAMANetworkOpen]

Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US. https://t.co/O7VL0HmlaF

[JAMA Network Open @JAMANetworkOpen]

Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US. https://t.co/O7VL0HmlaF

[Alex Melamed @headofmelon]

Thanks @IJGConline and @pedroramirezMD for this great honor.

[IJGC @IJGConline]

📣 Great news!!!
Dr. Alexander Melamed joins the #IJGC #AssociateEditors team 🔥 🔥

Welcome Alex!🤩

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4

[Alex Melamed @headofmelon]

@just_cameron @arieda_muco

[Alex Melamed @headofmelon]

@GeorgiaTomova @IntJEpidemiol Yikes

[Alex Melamed @headofmelon]

@ebonycartermd @UNC They are lucky to have you!